F-star Presents New Data on OX40/CD137 Tetravalent Bispecific Antibody at the SITC 2019 Annual Meeting
F-star Therapeutics (“F-star”), a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2™) antibodies, today announces that new preclinical data on FS120, a mAb² product candidate targeting OX40 and CD137, will be presented at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting in National Harbor, Maryland, United States, being held from 06 - 10 November 2019.
FS120 is a potentially best-in-class dual agonist that has the potential to overcome cancer resistance by simultaneously engaging OX40 (CD134, TNFRSF4) and CD137 (4-1BB), two receptors found on the surface of tumor-infiltrating lymphocytes. Targeting this class of receptors using bispecific tetravalent binding mobilizes multiple arms of the immune system, which research shows is essential for eliminating tumors. F-star’s preclinical data demonstrated that FS120’s crosslink-dependent approach has the potential to provide therapeutic benefit, for example in combination with checkpoint antagonists, and reverse T cell exhaustion in immunosuppressive tumor environments.
Neil Brewis, CSO of F-star said “Recent clinical trials involving agonist molecules have reported that a meaningful anti-cancer response is often associated with liver toxicity, in line with preclinical observations. F-star’s OX40/CD137 mAb² antibody is showing preclinical evidence that an effective tumor-killing response can be decoupled from liver inflammation. We look forward to progressing FS120 into the clinic as we aim to potentially improve treatment outcomes for patients with difficult-to-treat cancers.”
Some CD137 agonist antibodies have been shown to induce adverse effects either in clinical or in preclinical studies as they constitutively activate T cells and thus release cytotoxic immunity outside of the tumor. In contrast, FS120 is designed to mitigate off-target toxicity through conditional, crosslink-dependent activation upon binding to both OX40 and CD137, which are predominantly present on T cells in the tumor microenvironment.
F-star expects to submit an IND application for FS120 during the fourth quarter of 2019.
Details of the poster are below:
Crosslink-independent CD137 agonism is associated with liver inflammation
Abstract poster number: P775
Poster hall location: Prince George AB
Poster hall hours: 07:00 to 20:00 on Friday 08 November 2019
Poster presentation hours: 12:30 to 14:00 and 18:30 to 20:00 on Friday 08 November 2019
- ENDS -
F-star is a clinical-stage immuno-oncology company singularly focused on transforming the lives of patients with cancer through the development of its innovative tetravalent mAb2 bispecific antibodies. With four distinct binding sites in a natural human antibody format, F-star believes its proprietary approach will overcome many of the challenges facing current immuno-oncology therapies. F-star’s vision is to transform the treatment of cancer through the development of differentiated and well-tolerated mAb2 bispecific antibodies, which are designed to simultaneously address multiple immune evasion pathways that limit the effect of current immuno-oncology therapies.
mAb2™ is a trademark of F-star.
For investor enquiries
VP Investor Relations & Communications
+1 240 543 7970
Consilium Strategic Communications
Chris Gardner, Sue Stuart, David Daley
Tel: +44 (0)20 3709 5700
For media enquiries
+44 (0)1223 948 094
+44 (0)7392 080 279
Catherine London, US President
Tel: +1 917-763-2709
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Key Leadership Appointments Support Syngenta’s Continued Investment and Commitment to European Seeds Business27.5.2020 10:00:00 CEST | Press release
Syngenta has announced three strategic leadership appointments supporting the continued growth and investment in its European and global Seeds business. Gaël Hili, currently Crop Protection Head East Europe, is appointed Regional Director for Europe, Africa and Middle East (EAME) Seeds, taking over leadership of the region from Justin Wolfe, who has served as Regional Director EAME Seeds since 2018 and is appointed Regional Director for North America Seeds. “The important European seeds market is a must-win for Syngenta. Under Justin’s leadership, we have created a specialized Seeds organization, enabling us to bring growers the deep agronomic advice they need,” said Jeff Rowe, President Syngenta Seeds. “We have significantly increased the size of our grower-facing commercial and technical teams, and have expanded our corn and sunflower portfolio.” Gaël Hili joined Syngenta in 2017 as Head Europe East, and under his leadership, the team grew market share across both the Seeds and Crop
Jefferies to Hold Global Coronavirus Relief Charity Day Today Dedicated to the Memory of Peg Broadbent27.5.2020 09:00:00 CEST | Press release
Jefferies announced that it is holding its Global Coronavirus Relief Charity Day today. The firm and its staff will contribute to global charities and relief efforts to assist those suffering from the devastation caused by the Coronavirus global pandemic and will offer investors around the world the opportunity to join these efforts by trading with Jefferies. Jefferies will dedicate this entire effort to their late CFO Peg Broadbent, who was a victim of this terrible disease. As previously announced, Jefferies will donate net commissions from trading today, Wednesday, May 27th, for all global trading in equities, fixed income and foreign exchange by the firm’s clients. In addition, Jefferies as a firm will donate $1 million directly, and all 3,822 employees worldwide will be given the opportunity to donate to these efforts. These contributions will be allocated to a series of charities on the front lines in fighting this ongoing global pandemic and providing urgently needed relief for
MILSPED GROUP Relies on the Shippeo Platform to Meet the Growing Real-time Transportation Visibility Needs of Its Customers27.5.2020 09:00:00 CEST | Press release
Milšped, a leading international transport and logistics group, has chosen Shippeo, the European leader in supply chain visibility, to track in real-time all of its FTL and LTL operations operated by both its own fleet and its subcontracting partners. The large expertise of Shippeo in managing complex LTL operations in Europe has been a key decision criterion for Milšped to adopt the visibility platform. Milšped Group provides numerous integrated services, including customs clearance and brokerage, organization of international and domestic transportation and distribution, as well as warehousing solutions. The Serbian group has a strong presence throughout the Balkans as well as in Germany, Russia, China and the USA. Deputy Director for international transport Marko Cavoski is thrilled to be working with Shippeo. It is part of their strategy to invest in innovative solutions to lead in customer satisfaction. “As a 3PL, we work with more than 580 subcontractors on well over 200,000 orde
REPLY: Gartner Names Reply a Visionary in the 2020 Magic Quadrant for Warehouse Management Systems27.5.2020 09:00:00 CEST | Press release
Gartner, a leading IT research and strategic consulting firm, has positioned Reply, specialised in the design and implementation of solutions based on new communication channels and digital media, among the Visionaries in their “Magic Quadrant for Warehouse Management Systems” 2020. The report evaluates 15 vendors, focusing on warehouse management systems, software applications that support companies in optimising the execution of warehouse or distribution centre processes. Reply has been named in the Visionaries quadrant thanks to its proprietary suites: https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.reply.com%2Flea-reply%2Fen%2F&esheet=52225582&newsitemid=20200527005029&lan=en-US&anchor=LEA+ReplyTM&index=1&md5=25068938af51b5eec2b816283a93627b LEA ReplyTM and https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.reply.com%2Fclick-reply%2Fen%2F&esheet=52225582&newsitemid=20200527005029&lan=en-US&anchor=Click+ReplyTM&index=2&md5=074a995de316106a29d
SmartStream Extends Public API to Promote Access to Collateral Management Technologies27.5.2020 09:00:00 CEST | Press release
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today extended its Public API (Application Programming Interface) for collateral management, to enable its clients with faster access technology to better service their individual business needs. The approach has been taken to deliver a Public API which allows clients to have direct programmatic access to SmartStream’s TLM Collateral Management solution. This helps to lower the total cost of ownership, provides backward compatibility and future-proofs the solution for new operational requirements, with minimal disruption to the clients’ business. TLM Collateral Management has extended the rich functionality of its Public API to include collateral movements notifications. The technology has been designed to provide collateral movement and settlement views for the early indication of collateral fails. Other functionality includes, but are not limited to, workflow automation and agreement u
Devexperts Launches DXtrade as a SaaS Trading Platform for FX/CFD Brokers27.5.2020 08:00:00 CEST | Press release
Devexperts, a software provider for the financial industry, launched DXtrade, a new SaaS (Software-as-a-Service) trading platform for the retail FX and CFD industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005154/en/ DXtrade, a SaaS trading platform for CFD Brokers (Graphic: Business Wire) DXtrade is an off the shelf trading solution for CFD brokers with robust risk management and back office applications. Its flexibility in settings allows brokers to achieve their ideal setup in both their trading platform front ends and brokerage operations. DXtrade has been designed as a trading platform that allows brokers to differentiate themselves from the wider market as all layouts and setups of the platform are determined by the broker. This high degree of automation and customisation also extends to the back-end configurations where brokers can set up limits, rebates, margins, spreads, and client execution on instrume